Tag

Amgen

4 stories

FDA Apr 8, 2026

Lilly's Foundayo Clears FDA; Novo's Oral Wegovy Holds 5-Point Efficacy Lead

Lilly's oral obesity pill approved but trails Novo on weight loss. Pharma's M&A sprint added $7.9B in deals and Trump's tariffs landed with carveouts.

FDA Apr 7, 2026

TrumpRx Lists AbbVie's Humira at $950/Month Next to Cheaper Biosimilars

White House added Humira to TrumpRx at $950/month, the same site that already lists cheaper Pfizer and Amgen biosimilars.

FDA Apr 7, 2026

Amgen's Tepezza Just Got Injectable Data. So Did Viridian.

Amgen's subcutaneous Tepezza cleared Phase 3 as Viridian Therapeutics competes in the same thyroid eye disease market. Both are racing to file with FDA.

FDA Apr 6, 2026

Amgen's $27.8B Drug Gets Easier — Tepezza Shot Matches IV

Amgen's phase 3 shows subcutaneous Tepezza via on-body injector hits 77% response rate, matching IV efficacy, potentially expanding the flat $1.9B drug's reach.